

Ref. No: 1251
Date: 0810/24
Subject: intra-vitreous injections

REQUEST

How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2024:

- Aflibercept
- Bevacizumab - Avastin
- Bevacizumab - Biosimilar
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis (pre-filled syringes)
- Ranibizumab - Lucentis (vials)
- Ranibizumab - Ongavia
- Ranibizumab – Ximluci

RESPONSE

Number of Injections/Implants: May to August 2024:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	724	130	169
Bevacizumab	4	0	0
Dexamethasone	0	4	3
Faricimab	307	94	2
Ranibizumab - Lucentis	0	0	0
Ranibizumab - Ongavia	252	44	5
Ranibizumab - Ximluci			